Pieter Martens Selected Research

Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)

12/2021	Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study.
2/2021	Determinants of maximal dose titration of sacubitril/valsartan in clinical practice.
1/2021	Diuretic response and effects of diuretic omission in ambulatory heart failure patients on chronic low-dose loop diuretic therapy.
8/2020	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
1/2020	Measures of Loop Diuretic Efficiency and Prognosis in Chronic Kidney Disease.
11/2019	Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.
11/2018	Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
8/2018	Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low.
1/2018	Value of routine investigations to predict loop diuretic down-titration success in stable heart failure.
7/2017	Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pieter Martens Research Topics

Disease

58	Heart Failure 04/2022 - 04/2015
6	Iron Deficiencies 01/2022 - 01/2017
4	Chronic Renal Insufficiency 09/2021 - 10/2019
3	Inflammation (Inflammations) 09/2021 - 01/2018
3	Body Weight (Weight, Body) 10/2020 - 03/2017
2	Type 2 Diabetes Mellitus (MODY) 05/2022 - 06/2020
2	Left Ventricular Dysfunction 04/2022 - 02/2022
2	Myocardial Infarction 04/2022 - 02/2022
2	Dyspnea (Shortness of Breath) 01/2021 - 01/2018
2	Cardiomyopathies (Cardiomyopathy) 04/2020 - 07/2017
2	Ventricular Tachycardia 10/2019 - 12/2017
2	Ventricular Remodeling 07/2017 - 07/2017
2	Anemia 02/2017 - 01/2017
1	Hypernatremia 04/2022
1	Hyponatremia 04/2022
1	Atrial Fibrillation 01/2022
1	Heart Diseases (Heart Disease) 01/2022
1	Pleural Effusion (Pleural Effusions) 12/2021
1	Ascites 12/2021
1	Osteoporosis 09/2021
1	Heart Arrest (Cardiac Arrest) 09/2021
1	Diabetes Mellitus 08/2021
1	Hyperkalemia 02/2021
1	Bradycardia 02/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2020
1	Fibrosis (Cirrhosis) 01/2020
1	Mitral Valve Insufficiency (Mitral Regurgitation) 12/2019
1	Ventricular Premature Complexes (Premature Ventricular Contraction) 10/2019
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 10/2019
1	Cardio-Renal Syndrome 04/2019
1	Neoplasms (Cancer) 01/2019
1	Edema (Dropsy) 01/2018
1	Pulmonary Hypertension 01/2018
1	Hematologic Diseases (Blood Diseases) 01/2018
1	Pathologic Processes 09/2017
1	Chronic Kidney Failure (Chronic Renal Failure) 03/2017
1	Glycosuria 03/2017
1	Atherosclerosis 01/2017
1	Kidney Diseases (Kidney Disease) 01/2017
1	Bundle-Branch Block (Fascicular Block) 04/2015
1	Insulinoma 06/2014

Drug/Important Bio-Agent (IBA)

10	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 12/2021 - 07/2017
9	DiureticsIBA 01/2022 - 07/2017
9	sacubitril and valsartan sodium hydrate drug combinationIBA 12/2021 - 01/2018
8	SodiumIBA 04/2022 - 01/2017
5	IronIBA 01/2022 - 01/2017
4	CreatinineIBA 08/2021 - 01/2018
4	Glucose (Dextrose)FDA LinkGeneric 10/2020 - 01/2017
3	Acetazolamide (Diamox)FDA LinkGeneric 01/2022 - 11/2018
3	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 01/2018
3	Ferritins (Ferritin)IBA 10/2020 - 01/2019
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 08/2020 - 01/2018
3	Natriuretic PeptidesIBA 01/2020 - 01/2018
2	Eplerenone (Inspra)FDA LinkGeneric 04/2022 - 01/2018
2	ferric carboxymaltoseIBA 01/2022 - 10/2020
2	ElectrolytesIBA 01/2021 - 01/2019
2	Mineralocorticoid Receptor AntagonistsIBA 01/2021 - 01/2019
2	Spironolactone (Aldactone)FDA LinkGeneric 01/2021 - 04/2019
2	Transferrin (beta 2 Transferrin)IBA 12/2019 - 01/2019
2	Sodium-Glucose Transporter 2 InhibitorsIBA 03/2017 - 01/2017
2	Hemoglobins (Hemoglobin)IBA 02/2017 - 01/2017
1	Sodium-Glucose Transport ProteinsIBA 05/2022
1	MagnesiumIBA 02/2022
1	Furosemide (Lasix)FDA LinkGeneric 12/2021
1	TroponinIBA 09/2021
1	MineralsIBA 09/2021
1	Phosphorus (Red Phosphorus)IBA 09/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	dapagliflozinIBA 10/2020
1	Technetium (Technetium 99m)IBA 04/2020
1	Angiotensin Receptor AntagonistsIBA 01/2020
1	Polyvinyl Chloride (PVC)IBA 10/2019
1	Carbonic Anhydrase InhibitorsIBA 11/2018
1	ChloridesIBA 08/2018
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2018
1	AldosteroneIBA 01/2018
1	A73025IBA 01/2018
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2018
1	Dobutamine FDA LinkGeneric 01/2018
1	Uronic AcidsIBA 01/2018
1	Neprilysin (Neutral Endopeptidase)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 09/2017
1	ReninIBA 07/2017
1	SaltsIBA 07/2017
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 03/2017
1	Pharmaceutical PreparationsIBA 03/2017
1	empagliflozinIBA 01/2017
1	Hormones (Hormone)IBA 06/2014
1	Hypoglycemic Agents (Hypoglycemics)IBA 06/2014
1	proinsulin-like growth factor IIIBA 06/2014
1	Insulin (Novolin)FDA Link 06/2014
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2014

Therapy/Procedure

23	Therapeutics 01/2022 - 12/2015
19	Cardiac Resynchronization Therapy 01/2022 - 04/2015
3	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 01/2022 - 12/2017
2	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2020 - 01/2017
2	Drug Tapering 08/2018 - 01/2018
1	Cardiac Rehabilitation 12/2018
1	Length of Stay 11/2018
1	Glycemic Control 03/2017